Voluntary Announcement Exclusive License Agreement for BA2101 in the Treatment of Respiratory System Diseases

2 CLDN 18.2-Targeted Drugs Granted ODD for Gastric Cancer in US

Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of gastric cancer (including cancer of gas...

Voluntary Announcement both BA1105 and BA1301 being Granted Orphan Drug Designations for Treatment of Gastric Cancer by FDA

Boan Biotech Obtains ANVISA GMP Certification

Boan Biotech announced today that it has received GMP certification from the Brazilian Agência Nacional de Vigilância Sanitária (ANVISA) for its biological product, Boyuno® (Bevaciz...

Voluntary Announcement the Company has Obtained GMP Certification for Boyuno from the Brazilian Agencia Nacional de Vigilancia Sanitaria

All Subjects Enrolled for Intl Phase 3 Study of Boan’s Denosumab

A meeting was also held in Germany to announce the results of the international pharmacokinetic similarity clinical (Phase 1) studyBoan Biotech recently announced that subject enrollment for the inter...

Voluntary Announcement Enrollment of Subjects Completed for International Multi-Center Comparative Clinical (Phase 3) Study of Denosumab Injection

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

Voluntary Announcement Voluntary Lock-up Undertakings by Certain Shareholders

Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA

December 27, 2023 -- Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer ...